secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001628280-23-025388
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q2 preliminary: sales $25.53B (+6.3%), EPS $1.96 (+8.9%)
------------------------------------------------------------

- Net earnings $5.14B vs $4.81B; diluted EPS $1.96 vs $1.80 YoY.
- MedTech sales $7.79B (+12.9%) driven by Abiomed and Electrophysiology growth.
- Pharmaceutical sales $13.73B (+3.1%); DARZALEX +22.4%, TREMFYA +18.3%, CARVYKTI $117M.
- Consumer Health sales $4.01B (+5.4%); OTC +12.0%, Skin Health/Beauty +2.0%.
- Preliminary results subject to adjustment; six-month net earnings fell 49.1% due to $7.2B other expense (Kenvue).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000162828023025388/0001628280-23-025388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000162828023025388/jnj-20230724.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-025388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer